Rebecca Lehto on Complementary Modalities During Lung Cancer Treatment

Durvalumab monotherapy as consolidation therapy in limited-stage small cell lung cancer produced a clinical benefit in patients from the phase 3 ADRIATIC trial.

Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.

Poor sleep quality among those with lung cancer and COPD emphasize the need to develop effective assessment strategies.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Older patients with cancer demonstrated a moderate to high symptom burden, leading to the need for routine symptom assessments and tailored management interventions.

Fast track designation has been granted by the FDA to PT217 for extensive stage small cell lung cancer with disease progression.